---
title: "TBIO.US (TBIO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TBIO.US/news.md"
symbol: "TBIO.US"
name: "TBIO.US"
parent: "https://longbridge.com/en/quote/TBIO.US.md"
datetime: "2026-05-21T13:49:30.339Z"
locales:
  - [en](https://longbridge.com/en/quote/TBIO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TBIO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TBIO.US/news.md)
---

# TBIO.US (TBIO.US) — Related News

### [Biotalys Reports Full-Year 2025 Financial Results and Business Highlights](https://longbridge.com/en/news/284496995.md)
*2026-04-29T05:01:04.000Z*
> Biotalys revealed significant business milestones and financial performances for the year 2025. The company reported a t

### [Terremoto wins $108m in Series C to drive cancer and rare disease programmes](https://longbridge.com/en/news/282981717.md)
*2026-04-16T09:39:21.000Z*
> Terremoto Biosciences has raised $108 million in a Series C financing round to advance its AKT-1 selective inhibitors fo

### [Telesia Extends Timetable for 2025 Accounts and Updates 2026 Financial Calendar](https://longbridge.com/en/news/279455103.md)
*2026-03-17T14:52:54.000Z*
> Telesia Extends Timetable for 2025 Accounts and Updates 2026 Financial Calendar

### [Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026](https://longbridge.com/en/news/278546012.md)
*2026-03-10T11:28:42.000Z*
> Satellos Bioscience (TSE:MSCL) reported positive interim data for its lead candidate SAT-3247 in Duchenne muscular dystr

### [Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy](https://longbridge.com/en/news/276264365.md)
*2026-02-18T19:27:29.000Z*
> Satellos Bioscience Inc. will host a virtual KOL event on February 24, 2026, featuring Dr. Kevin M. Flanigan to discuss 

### [Stocks in Play:  Satellos Bioscience Inc.](https://longbridge.com/en/news/275777320.md)
*2026-02-12T15:22:17.000Z*
> 10:21 AM EST - Satellos Bioscience Inc. : Today announced that the first participant has been dosed in BASECAMP, a three